As science developed, the traditional Sanger sequence failed to meet new requirements of low cost, high productivity, and speed at speed.
In recent years, with the discovery and enhancement of second generation sequencing technology, the gene sequencing speed has increased dramatically with a significant reduction in costs, making the widespread application of genome sequencing possible. Now, the entire personal genome sequencing is costing around $ 5,000, and is expected to drop below $ 1,000 in the next few years.
The rapid development of sequencing technology will enhance the massive accumulation of DNA sequencing data, accompanied by the accumulation of individual diseases, signs and other data at the same time. When we collect enough data, how we understand this data will be very important. On a micro level, generations of molecular biologists who study the effects of genes of biological traits appearing on the use of technologies such as gene excursion have made breakthroughs in many critical aspects. At the macro level, statistics and other data analysis techniques are presented to study the relationship between gene sequencing and biological phenotype. The accumulation of basic scientific research gradually brings breakthroughs in clinical applications.
There are now basically two types of clinical applications, one of which aims to screen diseases in ordinary people. It exposes people to future risks of cancer by measuring known genes associated with the location of the disease. The other aims to diagnose cancer and other deadly diseases. It is found in a series of drugs or more effective plans for some patients by testing the position of some genes.
Data from BBC research shows that the global total gene sequencing market increased from $ 7.941 million in 2007 to $ 4.5 billion in 2013, and will reach $ 11.7 billion in 2018 with a CAGR of 21.2%.
Currently, the de novo sequencing platform market is mainly acquired by several major manufacturers, including Illumina and Ion Torrent / Life Technologies (acquired Thermo Fisher in 2014) and 454 Life Sciences / Roche, etc.
Under these conditions, the next generation sequence (second generation sequence) technology appears. As an emerging industry, next-generation sequencing technology can be applied in clinical tests such as antibody discovery, the health industry, industrial and agricultural use of gene-oriented studies, as well as scientific research and development.
To stimulate the sequencing market for the next generation, we need to start by investing in more small and medium-sized industries focusing on this area.